Study of Serum Hepcidin Rate Variations During Menstrual Cycle (HEPMEN)
Hepcidin is the major hormone regulating Iron Metabolism. In a normal organism decrease iron stock causes a decrease in hepcidin synthesis thus promoting intestinal absorption of iron.
The interpretation of hepcidin dosage results requires to know the physiological variations of this hormone.
This study investigate whether there are significant variations in the values of serum hepcidin rates during the menstrual cycle in order to make recommendations on the practical dosage determination of hepcidin in premenopausal women.
Study Overview
Status
Conditions
Detailed Description
Hepcidin is the major hormone regulating Iron Metabolism. Synthesized primarily by hepatocytes, it interacts with the cellular iron exporter ferroportin, causing its internalization and preventing the release of iron from enterocytes and macrophages.
In a normal organism decrease iron stock causes a decrease in hepcidin synthesis thus promoting intestinal absorption of iron.
Since valid methods for the determination of hepcidin serum rate are available, this dosage is increasingly used to diagnosis iron metabolism pathologies, in particular iron overload. The interpretation of hepcidin dosage results requires to know physiological variations of this hormone.
Several works have shown that hepcidin varies according to a circadian cycle, that its values differ by sex and, in women, by age. As far as the investigators know, no study has focused on possible variations in serum hepcidin rates values during menstrual cycle in women. Yet this question seems relevant since it has been shown that during the menstrual cycle blood loss can cause significant iron and hemoglobin variations, which can significantly modulate the synthesis of hepcidin.
This study investigate whether there are significant variations in the values of serum hepcidin rates during the menstrual cycle in order to make recommendations on the practical dosage determination of hepcidin in premenopausal women.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Brest, France, 29200
- CHU Brest
-
Nantes, France, 44000
- CHU Nantes
-
Tours, France, 37000
- CHRU Tours
-
-
Bretagne
-
Rennes, Bretagne, France, 35000
- CHU Rennes
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Woman aged over 18 and under 45 years,
- Having given free and informed written consent,
- Having regular cycles (defined by a constant interval between periods of 28 to 30 days),
- Having periods for a duration of 4 + / - 1 days
- Not using contraception or using oral oestroprogestative contraception.
Exclusion Criteria:
- Contraceptive IUD
- Metrorrhagia
- Pregnancy,
- BMI under 18 kg / m² and above 30 kg / m²,
- Presence of at least one of the following abnormalities in serum iron balance : Hemoglobin <11.5 g / dl, transferrin saturation under 15% or greater than 50%, serum ferritin under 15μg / l or greater than 150 µg / l
- Active smoking or quit within the last 6 months
- Drinking more than 20 g of alcohol per day ,
- Iron supplementation or blood transfusion within 12 months before inclusion
- Blood donation within 3 months before inclusion,
- Stay in altitude> 1500 m in the previous month before inclusion
- Chronic inflammatory disease,
- Incapable people over 18 (judicial protection, guardianship) and persons deprived of their liberty.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Healthy women
Non interventional
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum hepcidin rates variations during the menstrual cycle
Time Frame: During the menstrual cycle (see description)
|
Time frame : depending on the calendar day of D1 as the following calendars (D1: first day after periods beginning)
|
During the menstrual cycle (see description)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Seric iron
Time Frame: During the menstrual cycle (see description)
|
Time frame : depending on the calendar day of D1 as the following calendars (D1: first day after periods beginning)
|
During the menstrual cycle (see description)
|
|
transferrin saturation
Time Frame: During the menstrual cycle (see description)
|
Time frame : depending on the calendar day of D1 as the following calendars (D1: first day after periods beginning)
|
During the menstrual cycle (see description)
|
|
serum transferrin
Time Frame: During the menstrual cycle (see description)
|
Time frame : depending on the calendar day of D1 as the following calendars (D1: first day after periods beginning)
|
During the menstrual cycle (see description)
|
|
serum ferritin
Time Frame: During the menstrual cycle (see description)
|
Time frame : depending on the calendar day of D1 as the following calendars (D1: first day after periods beginning)
|
During the menstrual cycle (see description)
|
|
hepcidin / ferritin rate
Time Frame: During the menstrual cycle (see description)
|
Time frame : depending on the calendar day of D1 as the following calendars (D1: first day after periods beginning)
|
During the menstrual cycle (see description)
|
|
hepcidin / transferrin saturation rate
Time Frame: During the menstrual cycle (see description)
|
Time frame : depending on the calendar day of D1 as the following calendars (D1: first day after periods beginning)
|
During the menstrual cycle (see description)
|
|
hepcidin / serum iron rate
Time Frame: During the menstrual cycle (see description)
|
Time frame : depending on the calendar day of D1 as the following calendars (D1: first day after periods beginning)
|
During the menstrual cycle (see description)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Fabrice lainé, MD, CHU de Rennes - CIC INSERM 0203
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2012-A01122-41
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Women
-
Near East University, TurkeyCompletedHealthy Postmenopausal Women | Serum CNP Levels | Healthy Reproductive Age Women | Healthy Perimenopausal WomenCyprus
-
University of PittsburghBill and Melinda Gates FoundationCompleted
-
Aziende Chimiche Riunite Angelini Francesco S.p.ACross Research S.A.CompletedHealthy WomenSwitzerland
-
Celal Bayar UniversityCompleted
-
H. Lundbeck A/SCompleted
-
USDA Beltsville Human Nutrition Research CenterCompleted
-
Supernus Pharmaceuticals, Inc.CompletedHealthy Lactating WomenUnited States
-
University of ChicagoEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHealthy Pregnant WomenUnited States
-
University of California, DavisCompletedHealthy, Postmenopausal WomenUnited States
-
Thar Pharmaceuticals, IncCompletedHealthy Postmenopausal WomenUnited States